Aerovate Historical Cash Flow

AVTE Stock  USD 2.53  0.02  0.80%   
Analysis of Aerovate Therapeutics cash flow over time is an excellent tool to project Aerovate Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 10.8 M or Net Borrowings of 2 M as it is a great indicator of Aerovate Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Aerovate Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aerovate Therapeutics is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.

About Aerovate Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Aerovate balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Aerovate's non-liquid assets can be easily converted into cash.

Aerovate Therapeutics Cash Flow Chart

At present, Aerovate Therapeutics' Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 11.9 M, whereas Change In Working Capital is projected to grow to (8.5 M).

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most accounts from Aerovate Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Aerovate Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.At present, Aerovate Therapeutics' Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 11.9 M, whereas Change In Working Capital is projected to grow to (8.5 M).

Aerovate Therapeutics cash flow statement Correlations

Aerovate Therapeutics Account Relationship Matchups

Aerovate Therapeutics cash flow statement Accounts

202020212022202320242025 (projected)
Change In Cash1.1M49.6M(31.8M)1.1M10.3M10.8M
Stock Based Compensation58K2.0M5.5M11.9M11.3M11.9M
Free Cash Flow(7.9M)(27.6M)(39.3M)(56.9M)(71.2M)(67.6M)
Change In Working Capital974K(6.5M)7.8M9.8M(9.0M)(8.5M)
Begin Period Cash Flow3.5M4.6M54.2M22.4M23.5M20.5M
Other Cashflows From Financing Activities12.8M63.5M396K2.2M1.5M1.4M
Other Non Cash Items719K16K(910K)(3.1M)(4.2M)(4.0M)
Total Cash From Operating Activities(7.9M)(27.4M)(39.1M)(56.8M)(71.2M)(67.6M)
Issuance Of Capital Stock6.4M190.5M(250K)44.9M23.9M22.7M
Net Income(9.6M)(23.0M)(51.5M)(75.5M)(69.6M)(66.1M)
Total Cash From Financing Activities8.9M190.5M396K46.0M25.4M50.2M
End Period Cash Flow4.6M54.2M22.4M23.5M33.8M26.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.44)
Return On Assets
(0.45)
Return On Equity
(0.75)
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.